Broadly neutralizing antibody-mediated protection of macaques against repeated intravenous exposures to simian-human immunodeficiency virus

被引:5
作者
Garber, David A. [1 ]
Guenthner, Patricia [1 ]
Mitchell, James [1 ]
Ellis, Shanon [1 ]
Gazumyan, Anna [2 ]
Nason, Martha [3 ]
Seaman, Michael S. [4 ]
McNicholl, Janet M. [1 ]
Nussenzweig, Michel C. [2 ,5 ]
Heneine, Walid [1 ]
机构
[1] Ctr Dis Control & Prevent, Lab Branch, Div HIV Aids Prevent, Atlanta, GA 30329 USA
[2] Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA
[3] NIAID, Biostat Res Branch, NIH, Rockville, MD USA
[4] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02115 USA
[5] Rockefeller Univ, Howard Hughes Med Inst, 1230 York Ave, New York, NY 10021 USA
关键词
broadly neutralizing antibody; HIV; intravenous; macaque; preexposure prophylaxis; simian human immunodeficiency virus; INJECTING DRUG-USE; HIV-INFECTION; MONOCLONAL-ANTIBODIES; PREEXPOSURE PROPHYLAXIS; PASSIVE TRANSFER; PEOPLE; TRANSMISSION; PREVENTION; POTENT; WASHINGTON;
D O I
10.1097/QAD.0000000000002934
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: The opioid epidemic has increased parentally acquired HIV infection. To inform the development of a long-acting prevention strategy, we evaluated the protective efficacy of broadly neutralizing antibodies (bNAbs) against intravenous simian-human immunodeficiency virus (SHIV) infection in macaques. Design: Five cynomolgus macaques were injected once subcutaneously with 10-1074 and 3BNC117 (10 mg each kg(-1)) and were repeatedly challenged intravenously once weekly with SHIVAD8-EO (130 TCID50), until infection was confirmed via plasma viral load assay. Two control macaques, which received no antibody, were challenged identically. Methods: Plasma viremia was monitored via RT-qPCR assay. bNAb concentrations were determined longitudinally in plasma samples via TZM-bl neutralization assays using virions pseudotyped with 10-1074-sensitive (X2088_c9) or 3BNC117-sensitive (Q769.d22) HIV envelope proteins. Results: Passively immunized macaques were protected against a median of five weekly intravenous SHIV challenges, as compared to untreated controls, which were infected following a single challenge. Of the two bNAbs, 10-1074 exhibited relatively longer persistence in vivo. The median plasma level of 10-1074 at SHIV breakthrough was 1.1 mu g ml(-1) (range: 0.6-1.6 mu g ml(-1)), whereas 3BNC117 was undetectable. Probit modeling estimated that 6.6 mu g ml(-1) of 10-1074 in plasma corresponded to a 99% reduction in per-challenge infection probability, as compared to controls. Conclusions: Significant protection against repeated intravenous SHIV challenges was observed following administration of 10-1074 and 3BNC117 and was due primarily to 10-1074. Our findings extend preclinical studies of bNAb-mediated protection against mucosal SHIV acquisition and support the possibility that intermittent subcutaneous injections of 10-1074 could serve as long-acting preexposure prophylaxis for persons who inject drugs.
引用
收藏
页码:1567 / 1574
页数:8
相关论文
共 59 条
  • [1] Opioid Use Fueling HIV Transmission in an Urban Setting: An Outbreak of HIV Infection Among People Who Inject Drugs-Massachusetts, 2015-2018
    Alpren, Charles
    Dawson, Erica L.
    John, Betsey
    Cranston, Kevin
    Panneer, Nivedha
    Fukuda, H. Dawn
    Roosevelt, Kathleen
    Klevens, R. Monina
    Bryant, Janice
    Peters, Philip J.
    Lyss, Sheryl B.
    Switzer, William M.
    Burrage, Amanda
    Murray, Ashley
    Agnew-Brune, Christine
    Stiles, Tracy
    McClung, Paul
    Campbell, Ellsworth M.
    Breen, Courtney
    Randall, Liisa M.
    Dasgupta, Sharoda
    Onofrey, Shauna
    Bixler, Danae
    Hampton, Kischa
    Jaeger, Jenifer Leaf
    Hsu, Katherine K.
    Adih, William
    Callis, Barry
    Goldman, Linda R.
    Danner, Susie P.
    Jia, Hongwei
    Tumpney, Matthew
    Board, Amy
    Brown, Catherine
    DeMaria, Alfred, Jr.
    Buchacz, Kate
    [J]. AMERICAN JOURNAL OF PUBLIC HEALTH, 2020, 110 (01) : 37 - 44
  • [2] Anderson DJ, 2017, AIDS, V31, P1505, DOI [10.1097/QAD.0000000000001521, 10.1097/qad.0000000000001521]
  • [3] [Anonymous], 2018, PREEXP PROPH PREV HI
  • [4] Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
    Baba, TW
    Liska, V
    Hofmann-Lehmann, R
    Vlasak, J
    Xu, WD
    Ayehunie, S
    Cavacini, LA
    Posner, MR
    Katinger, H
    Stiegler, G
    Bernacky, BJ
    Rizvi, TA
    Schmidt, R
    Hill, LR
    Keeling, ME
    Lu, YC
    Wright, JE
    Chou, TC
    Ruprecht, RM
    [J]. NATURE MEDICINE, 2000, 6 (02) : 200 - 206
  • [5] Systematic review of HIV treatment adherence research among people who inject drugs in the United States and Canada: evidence to inform pre-exposure prophylaxis (PrEP) adherence interventions
    Bazzi, Angela R.
    Drainoni, Mari-Lynn
    Biancarelli, Dea L.
    Hartman, Joshua J.
    Mimiaga, Matthew J.
    Mayer, Kenneth H.
    Biello, Katie B.
    [J]. BMC PUBLIC HEALTH, 2019, 19 (1)
  • [6] Implementation of a three-tiered approach to identify and characterize anti-drug antibodies raised against HIV-specific broadly neutralizing antibodies
    Bharadwaj, Pranay
    Riekofski, Cassidy
    Lin, Shu
    Seaman, Michael S.
    Garber, David A.
    Montefiori, David
    Sarzotti-Kelsoe, Marcella
    Ackerman, Margaret E.
    Weiner, Joshua A.
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 2020, 479
  • [7] Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs
    Biello, K. B.
    Bazzi, A. R.
    Mimiaga, M. J.
    Biancarelli, D. L.
    Edeza, A.
    Salhaney, P.
    Childs, E.
    Drainoni, M. L.
    [J]. HARM REDUCTION JOURNAL, 2018, 15
  • [8] Detailed Transmission Network Analysis of a Large Opiate-Driven Outbreak of HIV Infection In the United States
    Campbell, Ellsworth M.
    Jia, Hongwei
    Shankar, Anupama
    Hanson, Debra
    Luo, Wei
    Masciotra, Silvina
    Owen, S. Michele
    Oster, Alexandra M.
    Galang, Romeo R.
    Spiller, Michael W.
    Blosser, Sara J.
    Chapman, Erika
    Roseberry, Jeremy C.
    Gentry, Jessica
    Pontones, Pamela
    Duwve, Joan
    Peyrani, Paula
    Kagan, Ron M.
    Whitcomb, Jeannette M.
    Peters, Philip J.
    Heneine, Walid
    Brooks, John T.
    Switzer, William M.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2017, 216 (09) : 1053 - 1062
  • [10] Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic
    Caskey, Marina
    Klein, Florian
    Nussenzweig, Michel C.
    [J]. NATURE MEDICINE, 2019, 25 (04) : 547 - 553